Tolerance to hypophagia induced by prolonged treatment with a CB1 antagonist is related to the reversion of anorexigenic neuropeptide gene expression in the hypothalamus

Regulatory Peptides

Volumn 182, Issue 1, 2013, Pages 12-18

  Rorato, Rodrigo ^a   Miyahara, Cristiano ^a   Antunes Rodrigues, José ^a   Elias, Lucila Leico Kagohara ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

CART; CRF; Hypophagia; Rimonabant

Indexed keywords

CANNABINOID 1 RECEPTOR ANTAGONIST; MESSENGER RNA; NEUROPEPTIDE; NEUROPEPTIDE Y; PROTEIN C FOS; RIMONABANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FOOD INTAKE; GENE EXPRESSION; HYPOPHAGIA; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; MALE; MICRODISSECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RNA ISOLATION; WEIGHT GAIN;

EID: 84873943893     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2012.12.004     Document Type: Article

References (55)

1. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999, 58:315-348.
2. Bisogno T., Ligresti A., Di Marzo V. The endocannabinoid signalling system: biochemical aspects. Pharmacol Biochem Behav 2005, 81:224-238.
3. Di Marzo V., Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005, 8:585-589.
4. Williams C.M., Rogers P.J., Kirkham T.C. Hyperphagia in pre-fed rats following oral delta9-THC. Physiol Behav 1998, 65:343-346.
5. Williams C.M., Kirkham T.C. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1999, 143:315-317.
6. Jamshidi N., Taylor D.A. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 2001, 134:1151-1154.
7. Kirkham T.C., Williams C.M. Endogenous cannabinoids and appetite. Nutr Res Rev 2001, 14:65-86.
8. Di Marzo V., Goparaju S.K., Wang L., Liu J., Batkai S., Jarai Z., Fezza F., Miura G.I., Palmiter R.D., Sugiura T., Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001, 410:822-855.
9. Williams C.M., Kirkham T.C. Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol Biochem Behav 2002, 71:333-340.
10. Marsicano G., Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 1999, 11:4213-4225.
11. Mailleux P., Vanderhaeghen J.J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 1992, 48:655-668.
12. Schwartz M.W., Woods S.C., Porte D., Seeley R.J., Baskin D.G. Central nervous system control of food intake. Nature 2000, 404:661-671.
13. Cota D., Marsicano G., Tschöp M., Grübler Y., Flachskamm C., Schubert M., Auer D., Yassouridis A., Thöne-Reineke C., Ortmann S., Tomassoni F., Cervino C., Nisoli E., Linthorst A.C., Pasquali R., Lutz B., Stalla G.K., Pagotto U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003, 112:423-431.
14. Suzuki T., Kohno H., Sakurada T., Tadano T., Kisara K. Intracranial injection of thyrotropin releasing hormone (TRH) suppresses starvation-induced feeding and drinking in rats. Pharmacol Biochem Behav 1982, 17:249-253.
15. Morley J.E., Levine A.S., Rowland N.E. Minireview: stress-induced eating. Life Sci 1983, 32:2169-2182.
16. Vrang N., Larsen P.J., Kristensen P., Tang-Christensen M. Central administration of cocaine-amphetamine-regulated transcript activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 2000, 141:794-801.
17. Asakawa A., Inui A., Yuzuriha H., Nagata T., Kaga T., Ueno N., Fujino M.A., Kasuga M. Cocaine-amphetamine-regulated transcript influences energy metabolism, anxiety and gastric emptying in mice. Horm Metab Res 2001, 33:554-558.
18. Steward C.A., Horan T.L., Schuhler S., Bennett G.W., Ebling F.J. Central administration of thyrotropin releasing hormone (TRH) and related peptides inhibits feeding behavior in the Siberian hamster. Neuroreport 2003, 14:687-691.
19. Füzesi T., Sánchez E., Wittmann G., Singru P.S., Fekete C., Lechan R.M. Regulation of cocaine- and amphetamine-regulated transcript-synthesising neurons of the hypothalamic paraventricular nucleus by endotoxin; implications for lipopolysaccharide-induced regulation of energy homeostasis. J Neuroendocrinol 2008, 20:1058-1066.
20. Deli L., Wittmann G., Kalló I., Lechan R.M., Watanabe M., Liposits Z., Fekete C. Type 1 cannabinoid receptor-containing axons innervate hypophysiotropic thyrotropin-releasing hormone-synthesizing neurons. Endocrinology 2009, 150:98-103.
21. Verty A.N., Boon W.M., Mallet P.E., McGregor I.S., Oldfield B.J. Involvement of hypothalamic peptides in the anorectic action of the CB receptor antagonist rimonabant (SR 141716). Eur J Neurosci 2009, 29:2207-2216.
22. Colombo G., Agabio R., Diaz G., Lobina C., Reali R., Gessa G.L. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998, 63:PL113-PL117.
23. Vickers S.P., Webster L.J., Wyatt A., Dourish C.T., Kennett G.A. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 2003, 167:103-111.
24. Doyon C., Denis R.G., Baraboi E.D., Samson P., Lalonde J., Deshaies Y., Richard D. Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats. Diabetes 2006, 55:3403-3410.
25. Rorato R., Castro M., Borges B.C., Benedetti M., Germano C.M., Antunes-Rodrigues J., Elias L.L. Adrenalectomy enhances endotoxemia-induced hypophagia: higher activation of corticotrophin-releasing-factor and proopiomelanocortin hypothalamic neurons. Horm Behav 2008, 54:134-142.
26. Rorato R., Menezes A.M., Giusti-Paiva A., de Castro M., Antunes-Rodrigues J., Elias L.L. Prostaglandin mediates endotoxaemia-induced hypophagia by activation of pro-opiomelanocortin and corticotrophin-releasing factor neurons in rats. Exp Physiol 2009, 94:371-379.
27. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1997, Academic Press, San Diego.
28. Pertwee R.G. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005, 76:1307-1324.
29. Arnone M., Maruani J., Chaperon F., Thiébot M.H., Poncelet M., Soubrié P., Le Fur G. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1997, 132:104-106.
30. Rowland N.E., Mukherjee M., Robertson K. Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology (Berl) 2001, 159:111-116.
31. Howlett A.C., Reggio P.H., Childers S.R., Hampson R.E., Ulloa N.M., Deutsch D.G. Endocannabinoid tone versus constitutive activity of cannabinoid receptors. Br J Pharmacol 2011, 163:1329-1343.
32. Silvestri C., Ligresti A., Di Marzo V. Peripheral effects of the endocannabinoids system in energy homeostasis: adipose tissue, liver and skeletal muscle. Rev Endocr Metab Disord 2011, 12:153-162.
33. Perwitz N., Wenzel J., Wagner I., Büning J., Drenckhan M., Zarse K., Ristow M., Lilienthal W., Lehnert H., Klein J. Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes. Diabetes Obes Metab 2010, 12:158-166.
34. Quarta C., Bellocchio L., Mancini G., Mazza R., Cervino C., Braulke L.J., Fekete C., Latorre R., Nanni C., Bucci M., Clemens L.E., Heldmaier G., Watanabe M., Leste-Lassere T., Maitre M., Tedesco L., Fanelli F., Reuss S., Klaus S., Srivastava R.K., et al. CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab 2010, 11:273-285.
35. Jbilo O., Ravinet-Trillou C., Arnone M., Buisson I., Bribes E., Péleraux A., Pénarier G., Soubrié P., Le Fur G., Galiègue S., Casellas P. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005, 19:1567-1569.
36. Mølhøj S., Hansen H.S., Schweiger M., Zimmermann R., Johansen T., Malmlöf K. Effect of the cannabinoid receptor-1 antagonist rimonabant on lipolysis in rats. Eur J Pharmacol 2010, 646:38-45.
37. Cota D., Steiner M.A., Marsicano G., Cervino C., Herman J.P., Grübler Y., Stalla J., Pasquali R., Lutz B., Stalla G.K., Pagotto U. Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology 2007, 148:1574-1581.
38. Howlett A.C., Fleming R.M. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 1984, 26:532-538.
39. Howlett A.C. Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol 1985, 27:429-436.
40. Rubino T., Viganò D., Zagato E., Sala M., Parolaro D. In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: behavioral and cellular responses after acute and chronic treatments. Synapse 2000, 35:8-14.
41. Suda T., Yajima F., Tomori N., Demura H., Shizume K. In vitro study of immunoreactive corticotropin-releasing factor release from the rat hypothalamus. Life Sci 1985, 37:1499-1505.
42. Spengler D., Rupprecht R., Van L.P., Holsboer F. Identification and characterization of a 3',5'-cyclic adenosine monophosphate-responsive element in the human corticotropin-releasing hormone gene promoter. Mol Endocrinol 1992, 6:1931-1941.
43. Rorato R., Reis W.L., Carvalho Borges B.D., Antunes-Rodrigues J., Kagohara Elias L.L. Cannabinoid CB(1) receptor restrains accentuated activity of hypothalamic corticotropin-releasing factor and brainstem tyrosine hydroxylase neurons in endotoxemia-induced hypophagia in rats. Neuropharmacology 2012, 63:154-160.
44. Sawchenko P.E., Swanson L.W. Immunohistochemical identification of neurons in the paraventricular nucleus of the hypothalamus that project to the medulla or to the spinal cord in the rat. J Comp Neurol 1982, 205:260-272.
45. Verty A.N., Allen A.M., Oldfield B.J. The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure. Obesity (Silver Spring) 2009, 17:254-261.
46. Kristensen P., Judge M.E., Thim L., Ribel U., Christjansen K.N., Wulff B.S., Clausen J.T., Jensen P.B., Madsen O.D., Vrang N., Larsen P.J., Hastrup S. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 1998, 393:72-76.
47. Wang C., Billington C.J., Levine A.S., Kotz C.M. Effect of CART in the hypothalamic paraventricular nucleus on feeding and uncoupling protein gene expression. Neuroreport 2000, 11:3251-3255.
48. Osei-Hyiaman D., Depetrillo M., Harvey-White J., Bannon A.W., Cravatt B.F., Kuhar M.J., Mackie K., Palkovits M., Kunos G. Cocaine- and amphetamine-related transcript is involved in the orexigenic effect of endogenous anandamide. Neuroendocrinology 2005, 81:273-282.
49. Di S., Malcher-Lopes R., Halmos K.C., Tasker J.G. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J Neurosci 2003, 23:4850-4857.
50. Gamber K.M., Macarthur H., Westfall T.C. Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuropharmacology 2005, 49:646-652.
51. Hentges S.T., Low M.J., Williams J.T. Differential regulation of synaptic inputs by constitutively released endocannabinoids and exogenous cannabinoids. J Neurosci 2005, 25:9746-9751.
52. Sinnayah P., Jobst E.E., Rathner J.A., Caldera-Siu A.D., Tonelli-Lemos L., Eusterbrock A.J., Enriori P.J., Pothos E.N., Grove K.L., Cowley M.A. Feeding induced by cannabinoids is mediated independently of the melanocortin system. PLoS One 2008, 3:e2202.
53. Thornton-Jones Z.D., Kennett G.A., Benwell K.R., Revell D.F., Misra A., Sellwood D.M., Vickers S.P., Clifton P.G. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacol Biochem Behav 2006, 84:353-359.
54. de Ligt R.A., Kourounakis A.P., Ijzerman A.P. Inverse agonism at G protein-coupled receptors: (patho) physiological relevance and implications for drug discovery. Br J Pharmacol 2000, 130:1-12.
55. Molinoff P.B., Aarons R.D. Effects of drugs on beta-adrenergic receptors on human lymphocytes. J Cardiovasc Pharmacol 1983, 5:S63-S67.